Rosetta Puts Blood-Based Cancer Screen on Back Burner to Refocus on miRNA Diagnostics
December 31, 2009
Rosetta Puts Blood-Based Cancer Screen on Back Burner to Refocus on miRNA Diagnostics
The news wasn't a complete surprise given the general difficulties in measuring and interpreting blood-borne miRNA signatures, as well as the firm's own admission in September that "technical obstacles" had been stymieing its efforts to develop the screen.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Rosetta Signs Marketing Deal for Mesothelioma Test with Tort Claims Administration Firm
June 16, 2011 / Gene Silencing News - Rosetta Regains US Rights to miRNA Cancer Diagnostics, Addresses QC Issue at Diagnostics Lab
December 2, 2010 / Gene Silencing News - Rosetta Genomics Unveils Two New Development-Stage Tests
September 9, 2010 / Gene Silencing News - Rosetta Licenses Greek miRNA Dx Rights to Genekor
July 29, 2010 / Gene Silencing News - Rosetta Inks Commercialization Deal for miRNA Tests with Genetic Technologies
October 22, 2009 / Gene Silencing News